Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of EDP-721 Alone and in Combination with EDP-514 in Hepatitis B
NCT04971512Phase 1Terminated
- Sponsor
- Enanta Pharmaceuticals
- Start
- Aug 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of EDP-721 in Chronic Hepatitis B (CHB) (6 arms), sponsored by Enanta Pharmaceuticals. Primary endpoint: Safety measured by adverse events up to 98 Days. Started Aug 2021; status: terminated.
02
Drugs
EDP-721
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04971512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04971512.